Navigation Links
Azithromycin Doesn't Always Help Lungs in Cystic Fibrosis Patients
Date:5/4/2010

Antibiotic helped some with respiratory disease, but more study needed

TUESDAY, May 4 (HealthDay News) -- Treatment with the antibiotic azithromycin doesn't improve the lung function of children and teens with cystic fibrosis, U.S. researchers report.

"A vicious cycle of infection and inflammation causes progressive lung destruction and premature death in patients with cystic fibrosis [CF]. Treatment strategies have therefore included both antimicrobial and anti-inflammatory agents," Dr. Lisa Saiman, of Columbia University in New York City, said in a news release.

Over the past decade, studies have suggested that azithromycin, an antibiotic with both antimicrobial and anti-inflammatory activity, benefits CF patients.

Azithromycin is recommended as therapy for CF patients with chronic infection with the bacteria Pseudomonas aeruginosa, but there has not been enough evidence to support the benefit of azithromycin in other patients with CF, the researchers wrote.

This study, which investigated the possible benefits of expanding the antibiotic therapy to CF patients without the pathogen, included 260 children and teens with CF who were not infected with P. aeruginosa. They were randomly selected to receive either azithromycin or a placebo. After 24 weeks of treatment, there was no difference in lung function between the two groups.

However, researchers found that when compared with the placebo group, the azithromycin group had 50 percent fewer pulmonary exacerbations and 27 percent fewer patients who had to begin new oral antibiotics (other than azithromycin). On average, they also showed a 1.3-pound weight gain and a 0.34-unit increase in body-mass index (important because CF patients often need to gain weight). There were no differences in treatment groups in the use of intravenous or inhaled antibiotics or hospitalizations, Saiman and colleagues added.

They also found that patients who took the antibiotic had less cough and less productive cough than those in the placebo group.

"Further studies of azithromycin are warranted to further investigate its potential use" in CF patients not infected with P. aeruginosa, the researchers concluded.

The study appears in the May 5 issue of the Journal of the American Medical Association.

More information

The U.S. National Library of Medicine has more about cystic fibrosis.



-- Robert Preidt



SOURCE:Journal of the American Medical Association, news release, May 5, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New studies on surgical options in inherited breast cancer show drastic treatment is not always best
2. SAN SnapShot Backup for VMWare - Does Your Backup Always Completes In Seconds, Is 1000x Faster and Costs 90% Less?
3. Rotary Clubs Always Pumped for World Water Day
4. Patient and doctor expectations from joint replacement surgeries not always aligned
5. Its Not Always Women and Children First
6. Liberal Thinking: It, and It Alone, Has Always Been the Force Behind Positive Social Changes in America
7. Methadone and Other Opioids Not Always Equivalent, Conversion Can Be Lethal
8. Top-rated hospitals dont always have superior outcomes
9. Research findings underscore needed action to safeguard lungs of young cancer survivors
10. New technique reduces tobacco smoke damage to lungs in mice
11. Discovery in Lungs May Lead to Treatment for Respiratory Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Worth, TX (PRWEB) , ... October 13, 2017 ... ... financial planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, ... young boy fighting to overcome a rare and deadly chromosome abnormality. , After ...
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology: